ערך בספרים למניה: cellectar.com (CLRB)

The experienced management of Cellectar Biosciences (CLRB) is effectively laying the groundwork for the registration of new drugs, as evidenced by the book value per share, which currently stands at 3.64. Leadership in developing precision delivery systems for radiopharmaceuticals is supported by robust R&D. Meanwhile, manufacturing and testing are outsourced to third-party contractors, allowing the company to focus on the development of therapeutic methods.

Cellectar Biosciences (CLRB) is developing a patent-protected niche in radiopharmaceuticals, where stringent FDA requirements and the complexity of isotope logistics create significant barriers to entry. An analysis of the book value per share—reflecting the difference between assets and liabilities per security—allows for an assessment of the real cost of capital and the company's resilience to shocks through the price action of this chart.